Oruka Competitors
| ORKA Stock | 35.49 2.17 6.51% |
Oruka Therapeutics vs Phio Pharmaceuticals Correlation
Very good diversification
The correlation between Oruka Therapeutics and PHIO is -0.35 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Oruka Therapeutics and PHIO in the same portfolio, assuming nothing else is changed.
Moving together with Oruka Stock
Moving against Oruka Stock
| 0.55 | OSE | OSE Pharma SA | PairCorr |
| 0.55 | RAC | Race Oncology | PairCorr |
| 0.46 | VCYT | Veracyte Earnings Call Tomorrow | PairCorr |
| 0.34 | VCEL | Vericel Corp Ord Earnings Call This Week | PairCorr |
Oruka Therapeutics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Oruka Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Oruka and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Oruka Therapeutics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Oruka Stock performing well and Oruka Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Oruka Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| BCDA | 2.54 | (0.08) | 0.00 | (0.16) | 0.00 | 5.93 | 19.36 | |||
| CELZ | 3.68 | (0.81) | 0.00 | (0.29) | 0.00 | 7.17 | 25.03 | |||
| HCWB | 5.00 | (2.39) | 0.00 | (0.74) | 0.00 | 8.72 | 42.74 | |||
| ACXP | 4.14 | (1.40) | 0.00 | (1.39) | 0.00 | 9.45 | 49.19 | |||
| APRE | 4.47 | (0.41) | 0.00 | (0.20) | 0.00 | 11.29 | 46.26 | |||
| ADIL | 3.15 | (1.74) | 0.00 | (2.53) | 0.00 | 5.70 | 34.48 | |||
| KPRX | 2.57 | (0.11) | 0.00 | (0.06) | 0.00 | 4.44 | 16.69 | |||
| NRSN | 4.51 | (0.11) | 0.00 | (0.12) | 0.00 | 12.82 | 34.62 | |||
| CDIO | 7.42 | 0.43 | 0.08 | 0.18 | 6.54 | 22.86 | 73.83 | |||
| PHIO | 4.47 | (0.24) | 0.00 | (0.10) | 0.00 | 7.34 | 56.33 |
Cross Equities Net Income Analysis
Compare Oruka Therapeutics and related stocks such as Biocardia, Creative Medical Tec, and HCW Biologics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BCDA | 135.6 K | 9.7 M | 305 K | 19 K | 234 K | 322 K | (10.3 M) | (12.3 M) | (14 M) | (14.7 M) | (15 M) | (12.6 M) | (11.9 M) | (11.6 M) | (7.9 M) | (7.2 M) | (6.8 M) |
| CELZ | 1.4 K | (24.1 K) | (25.6 K) | (27.3 K) | (28 K) | (30.8 K) | (766.1 K) | (2.7 M) | (13.7 M) | (8.5 M) | (36.3 M) | 19.2 M | (10.1 M) | (5.3 M) | (5.5 M) | (4.9 M) | (5.2 M) |
| HCWB | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (5.8 M) | (12.9 M) | (14.9 M) | (25 M) | (30 M) | (27 M) | (25.7 M) |
| ACXP | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (4.6 M) | (12.7 M) | (12.1 M) | (14.6 M) | (14.1 M) | (12.7 M) | (13.3 M) |
| APRE | (3.5 M) | (254 K) | (254 K) | (436.2 K) | (15.2 M) | (15.2 M) | (15.2 M) | (15.2 M) | (15.5 M) | (28.1 M) | (53.9 M) | (36.5 M) | (112.7 M) | (14.3 M) | (13 M) | (11.7 M) | (12.2 M) |
| ADIL | (818 K) | (818 K) | (818 K) | (818 K) | (818 K) | (818 K) | (420.2 K) | (1.1 M) | (11.6 M) | (8.6 M) | (10.9 M) | (19.4 M) | (12.7 M) | (7 M) | (13.2 M) | (11.9 M) | (12.5 M) |
| KPRX | (6 M) | (6 M) | (6 M) | (3.9 M) | (1.8 M) | (8.4 M) | (13.3 M) | (13.2 M) | (10.8 M) | (7.1 M) | (6.9 M) | (13.8 M) | (13.6 M) | (12.5 M) | 3.6 M | 3.2 M | 3.4 M |
| NRSN | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (2.8 M) | (4 M) | (12.3 M) | (10.1 M) | (10.2 M) | (9.2 M) | (9.6 M) |
| CDIO | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (605.2 K) | (620.4 K) | (4.7 M) | (8.4 M) | (8.4 M) | (7.5 M) | (7.2 M) |
| PHIO | (10.2 M) | (10.2 M) | (12.9 M) | (20.9 M) | (8.8 M) | (10.2 M) | (9 M) | (12.5 M) | (7.4 M) | (8.8 M) | (8.8 M) | (13.2 M) | (11.3 M) | (10.8 M) | (7.2 M) | (8.2 M) | (8.6 M) |
Oruka Therapeutics and related stocks such as Biocardia, Creative Medical Tec, and HCW Biologics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Oruka Therapeutics financial statement analysis. It represents the amount of money remaining after all of Oruka Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Oruka Therapeutics Competitive Analysis
The better you understand Oruka Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Oruka Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Oruka Therapeutics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Oruka Therapeutics Competition Performance Charts
Five steps to successful analysis of Oruka Therapeutics Competition
Oruka Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Oruka Therapeutics in relation to its competition. Oruka Therapeutics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Oruka Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Oruka Therapeutics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Oruka Therapeutics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Oruka Therapeutics position
In addition to having Oruka Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Agriculture ETFs Thematic Idea Now
Agriculture ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Agriculture ETFs theme has 11 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Agriculture ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Oruka Therapeutics Correlation with its peers. For information on how to trade Oruka Stock refer to our How to Trade Oruka Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oruka Therapeutics. Anticipated expansion of Oruka directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Oruka Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Oruka Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Oruka Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Oruka Therapeutics' market price to deviate significantly from intrinsic value.
It's important to distinguish between Oruka Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Oruka Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Oruka Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.